The Pharma Data

JANUARY 12, 2021

Biond Biologics announced today that it has entered into a potentially $1 billion global licensing agreement with Sanofi to take a joint stab at defeating advanced forms of cancer with a more comprehensive and expedited approach to immuno-oncology. . Keitma/Shutterstock.

Immune Response 52

Immune Response Clinical Trials Licensing Licensing 52

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. MRT5500 is being developed under a collaboration and license agreement between Sanofi Pasteur and Translate Bio. Expected to enroll 415 participants; interim results expected in Q3 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

OCTOBER 19, 2020

Immune responses following vaccination with PNEUMOVAX 23 (month 13) were comparable in both vaccination groups for the 15 serotypes in V114. Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies. Select Safety Information for PNEUMOVAX 23.

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

The Pharma Data

AUGUST 15, 2021

Important Safety Information for TICOVAC. Please see full prescribing information for TICOVAC here. About TBE TBE is a viral infection of the brain and spine, 2 transmitted to humans through the bite of an infected tick, 3 and less frequently by ingestion of unpasteurized milk or milk products from infected animals.

FDA Approval 52

FDA Approval Vaccine FDA Virus 52

The Pharma Data

OCTOBER 26, 2020

News information is not all-inclusive and updates are published once a week on Tuesdays. . . based company said the preventative medication boosts immune responses in older and younger adults against the novel coronavirus. FDA Actions. They expect to launch a Phase III trial of the drug in the first quarter of 2021. .

Vaccine 52

Vaccine FDA Approval FDA Clinical Trials 52

The Pharma Data

NOVEMBER 18, 2020

.” Ming-Tain Lai, PhD, Chief Scientific Officer at OBI Pharma stated, “In the trial, OBI-833 demonstrated a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses. Additional information can be found at www.obipharma.com. ” Presentation number: 397P / Poster: ID 680. About OBI Pharma.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

JULY 23, 2021

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing Information available at www.cvdvaccine-us.com. IMPORTANT SAFETY INFORMATION FROM U.S.

Vaccine 52

Vaccine Government Immune Response FDA 52

The Pharma Data

DECEMBER 11, 2020

Pfizer and BioNTech expect to file a Biologics License Application for possible full regulatory approval in 2021. Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing Information available at www.cvdvaccine.com.

Vaccine 52

Vaccine Clinical Trials Trials Licensing 52

The Pharma Data

DECEMBER 23, 2020

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. The antigen is processed naturally in the cell and triggers the desired T cell and antibody-mediated immune responses. About INOVIO.

DNA 40

DNA Vaccine Immune Response Clinical Trials 40

The Pharma Data

MAY 6, 2021

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including Full EUA Prescribing Information available at www.cvdvaccine.com. IMPORTANT SAFETY INFORMATION FROM U.S.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

JULY 21, 2021

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing Information available at www.cvdvaccine-us.com. IMPORTANT SAFETY INFORMATION FROM U.S.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

JUNE 24, 2021

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing Information available at www.cvdvaccine-us.com. IMPORTANT SAFETY INFORMATION FROM U.S.

Vaccine 52

Vaccine Clinical Trials Trials FDA 52

The Pharma Data

AUGUST 20, 2020

These results informed the selection of the BNT162b2 candidate for the pivotal Phase 2/3 global study in up to 30,000 participants that started in July 2020, which has to date enrolled more than 11,000 participants, including in areas with significant SARS-CoV-2 transmission. This press release features multimedia. and Germany.

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

The Pharma Data

DECEMBER 29, 2020

The analysis was prospectively designed to focus on patients who had not yet mounted their own immune response to SARS-CoV-2 (i.e., The EUA is temporary and does not take the place of a formal biologics license application (BLA) submission review and approval process and the use of the antibody cocktail remains investigational.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

DECEMBER 20, 2020

The primary endpoints of the study include safety and overall response rate, while secondary endpoints include progression-free survival, overall survival and immune response correlates. SELLAS’ lead product candidate, GPS, is licensed from MSK and targets the WT1 protein, which is present in an array of tumor types.

Immune Response 52

Immune Response Clinical Trials Therapies Trials 52

The Pharma Data

JANUARY 4, 2021

We believe our allogenic CAR-T platform is significantly stronger with chPD1 target licensed from Longwood University. Chimeric PD-1 T-cells also release cytokines to further initiate immune responses to eradicate the tumor cells. For more information, please visit the company’s website at www.kiromic.com.

Molecular Biology 40

Molecular Biology Therapies Immune Response Science 40

The Anticancer Fund

JUNE 23, 2023

Among 16 patients evaluable for best response, there were one complete response (Ewing sarcoma), three partial responses (Ewing sarcoma, glioblastoma multiforme, and alveolar rhabdomyosarcoma), and five patients with stable disease. However, this was not an efficacy trial and similar responses have been seen from chemo alone.

Drugs 52

Drugs Trials Clinical Trials Treatment 52

The Pharma Data

SEPTEMBER 9, 2020

During preclinical and clinical studies, BNT162b1 and BNT162b2 emerged as strong candidates based on assessments of safety and immune response. We routinely post information that may be important to investors on our website at www.Pfizer.com. The information contained in this release is as of September 7, 2020.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

The Pharma Data

OCTOBER 28, 2020

“We continue to see the strongest effects in patients who are most at risk for poor outcomes due to high viral load, ineffective antibody immune response at baseline, or pre-existing risk factors. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

DECEMBER 10, 2020

Data from this study, including longer term safety, comprehensive information on duration of protection, efficacy against asymptomatic SARS-CoV-2 infection, and safety and immunogenicity in adolescents 12 to 15 years of age will be gathered in the months ahead. The information contained in this release is as of December 10, 2020.

Vaccine 52

Vaccine Trials Clinical Trials Therapies 52

The Pharma Data

NOVEMBER 29, 2020

HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc.

Vaccine 52

Vaccine Clinical Trials Disease Therapies 52

The Pharma Data

SEPTEMBER 8, 2020

For more information, please visit [link]. For further information please visit www.gsk.com/about-us. For more information, visit www.merck.com and connect with us on Twitter , Facebook , Instagram , YouTube and LinkedIn. For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 8, 2020

For more information, please visit. For further information please visit. For more information, visit. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. For more information, visit.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

DECEMBER 17, 2020

AUTHORIZED USE AND IMPORTANT SAFETY INFORMATION. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter. Senior Vice President and Head of Global Clinical Development at Regeneron and lead author of the publication.

Hospitals 52

Hospitals Production Clinical Trials Therapies 52

The Pharma Data

MAY 15, 2023

5 GSK’s MenABCWY vaccine candidate combines the antigenic components of licensed meningococcal vaccines, Bexsero and Menveo. Bexsero is used as the comparator for the MenB immune responses induced by the MenABCWY vaccine in the trial, which is both the phase III trial for MenABCWY and confirmatory trial for Bexsero in the US.

Vaccine 40

Vaccine Immune Response Licensing Licensing 40

The Pharma Data

AUGUST 3, 2021

Certain financial information for 2021 and 2020 is presented on both a reported and a non-GAAP basis. announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses. 23% Net Income – Reported 1,390.2

Production 52

Production Marketing Research DNA 52

The Pharma Data

JUNE 26, 2021

We believe that mRNA technology could have several advantages for a seasonal flu application including the potential ability to demonstrate robust immune responses based on preclinical data to date, enable antigen specificity within a short timeframe from seasonal virus strain selection, and deploy agile manufacturing capacity.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

Agency IQ

MARCH 7, 2024

Changes — either slow drifts across time or more abrupt mutations — can occur within lineages, clades, and sub-clades; these changes, along with changes in which viruses are responsible for more cases of influenza in a given region and season, inform WHO vaccine strain recommendations for a given influenza season.

Vaccine 40

Vaccine FDA Virus Licensing 40

The Pharma Data

JANUARY 31, 2021

Delivery of viral antigens in potent vaccine vectors to elicit a strong immune response is a cornerstone of successful infectious disease vaccines,” said Karin Jooss, PhD, Executive Vice President of Research and Chief Scientific Officer of Gritstone. For more information, please visit gritstoneoncology.com. Source link.

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

Drug Target Review

FEBRUARY 28, 2024

Thanks to the efforts of passionate researchers whose preclinical work continues to inform development programmes at IN8bio and other companies, and investors who are beginning to recognise the cells’ distinct identity and potential, γδ T cells are poised to change the paradigm of T-cell therapies in the treatment of cancer.

Therapies 105

Therapies Engineering Molecular Biology Science 105

Codon

SEPTEMBER 29, 2024

At best, the corporations with the best models released weak versions to the public under non-commercial licenses. The systems themselves began to infer the existence of unknown biological modalities, extracting information from data never explicitly fed to them. It started small. Thoughts flowed with unprecedented clarity and speed.

Engineering 126

Engineering Virus DNA Therapies 126

The Pharma Data

SEPTEMBER 9, 2020

producing CD8+ T cell responses, which is thought to promote an anti-viral effect. In a preclinical murine model, a single IM immunization of BNT162b2 (0.2, CD4+ and CD8+ T-cells from splenocytes isolated from BNT162b2-immunized mice were strongly positive for IFN? Pfizer Disclosure Notice.

Vaccine 52

Vaccine RNA Clinical Trials Trials 52

The Pharma Data

JUNE 18, 2021

pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved based on immune responses. IMPORTANT SAFETY INFORMATION. Please see full prescribing information for PREVNAR 20 , INDICATIONS FOR PREVNAR 13 ® IN ADULTS. IMPORTANT SAFETY INFORMATION. Please see full prescribing information for PREVNAR 13 ®.

Vaccine 52

Vaccine FDA Approval FDA Disease 52

The Pharma Data

NOVEMBER 20, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load. AUTHORIZED USE AND IMPORTANT SAFETY INFORMATION.

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

The Pharma Data

SEPTEMBER 7, 2021

Bristol Myers Squibb has a global exclusive license to develop, manufacture and commercialize the Rockefeller University’s novel monoclonal antibody (“mAb”) duo treatment that neutralizes the SARS-CoV-2 virus for therapy or prevention of COVID-19. Contributions to Research, Life-Sciences Industry.

Clinical Trials 52

Clinical Trials Vaccine Virus Trials 52

The Pharma Data

NOVEMBER 21, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as REGEN-COV2 have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load. AUTHORIZED USE AND IMPORTANT SAFETY INFORMATION.

FDA 40

FDA Clinical Trials Hospitals Production 40

The Pharma Data

DECEMBER 20, 2020

This oncolytic virus has induced long-lasting antitumor immune responses and abscopal effects in several tumor models, and its activity is further enhanced through combination with an anti-PD-1 antibody treatment. More information is available at www.bioinvent.com. This information was brought to you by Cision [link].

Virus 52

Virus Trials Clinical Trials Clinical Development 52